| Zucca, Emanuele |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
| Terminated | 2 | 154 | Europe | Rituximab, Rituximab (MabThera), lenalidomide, Lenalidomide (Revlimid) | Swiss Group for Clinical Cancer Research | Lymphoma | 06/14 | 01/23 | | |
|
| Active, not recruiting | 2 | 112 | Europe | Chlorambucil, Rituximab i.v., Rituximab s.c. | International Extranodal Lymphoma Study Group (IELSG) | MALT Lymphoma | 03/16 | 09/28 | | |
IELSG30, NCT00945724 / 2009-011789-26: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis |
|
|
| Completed | 2 | 54 | Europe | Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate | International Extranodal Lymphoma Study Group (IELSG) | Large B-cell Diffuse Lymphoma of Testis | 06/19 | 09/23 | | |
| Completed | 2 | 44 | Europe | clarithromycin and lenalidomide | International Extranodal Lymphoma Study Group (IELSG) | Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | 11/19 | 12/24 | | |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
| Terminated | 2 | 190 | Europe | Ibrutinib, Imbruvica®, Rituximab, MabThera® | Swiss Group for Clinical Cancer Research, Nordic Lymphoma Group | Follicular Lymphoma | 12/22 | 07/23 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients |
|
|
| Active, not recruiting | 2 | 26 | Europe | Tafasitamab, MOR00208, Acalabrutinib, Calquence | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 09/27 | 03/28 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
| Raderer, Markus |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients |
|
|
| Active, not recruiting | 2 | 26 | Europe | Tafasitamab, MOR00208, Acalabrutinib, Calquence | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 09/27 | 03/28 | | |
NCT04268277: Pembrolizumab in MarginalzoneLymphoma a MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY |
|
|
| Terminated | N/A | 22 | Europe | Rituximab, Truxima, Pembrolizumab, Keytruda | University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD | Marginal Zone Lymphoma | 12/24 | 12/24 | | |
